Literature DB >> 21836609

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.

I H I M Hollink, Q Feng, A A Danen-van Oorschot, S T C J M Arentsen-Peters, L J Verboon, P Zhang, V de Haas, D Reinhardt, U Creutzig, J Trka, R Pieters, M M van den Heuvel-Eibrink, J Wang, C M Zwaan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21836609     DOI： 10.1038/leu.2011.210

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease.

Authors:  Marjolein Blink; Marry M van den Heuvel-Eibrink; Valerie de Haas; Jan-Henning Klusmann; Henrik Hasle; C Michel Zwaan
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

2.  Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia.

Authors:  Daria G Valerio; Jenny E Katsman-Kuipers; Joop H Jansen; Lonneke J Verboon; Valerie de Haas; Jan Stary; André Baruchel; Martin Zimmermann; Rob Pieters; Dirk Reinhardt; Marry M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 3.  DNMT3A in haematological malignancies.

Authors:  Liubin Yang; Rachel Rau; Margaret A Goodell
Journal:  Nat Rev Cancer       Date:  2015-02-19       Impact factor: 60.716

Review 4.  Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.

Authors:  Ashley Pandolfi; Laura Barreyro; Ulrich Steidl
Journal:  Stem Cells Transl Med       Date:  2013-01-24       Impact factor: 6.940

5.  Transcriptome Profiling of Pediatric Core Binding Factor AML.

Authors:  Chih-Hao Hsu; Cu Nguyen; Chunhua Yan; Rhonda E Ries; Qing-Rong Chen; Ying Hu; Fabiana Ostronoff; Derek L Stirewalt; George Komatsoulis; Shawn Levy; Daoud Meerzaman; Soheil Meshinchi
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

6.  BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.

Authors:  Helen Jayne Susan Stewart; Gillian Abigail Horne; Sarah Bastow; Timothy James Telfer Chevassut
Journal:  Cancer Med       Date:  2013-10-31       Impact factor: 4.452

7.  DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation.

Authors:  Junji Koya; Keisuke Kataoka; Tomohiko Sato; Masashige Bando; Yuki Kato; Takako Tsuruta-Kishino; Hiroshi Kobayashi; Kensuke Narukawa; Hiroyuki Miyoshi; Katsuhiko Shirahige; Mineo Kurokawa
Journal:  Nat Commun       Date:  2016-03-24       Impact factor: 14.919

8.  DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.

Authors:  H J Ferreira; H Heyn; M Vizoso; C Moutinho; E Vidal; A Gomez; A Martínez-Cardús; L Simó-Riudalbas; S Moran; E Jost; M Esteller
Journal:  Oncogene       Date:  2015-10-05       Impact factor: 9.867

Review 9.  Pediatric AML: From Biology to Clinical Management.

Authors:  Jasmijn D E de Rooij; C Michel Zwaan; Marry van den Heuvel-Eibrink
Journal:  J Clin Med       Date:  2015-01-09       Impact factor: 4.241

10.  Gene expression profiling of the DNMT3A R882 mutation in acute leukemia.

Authors:  Xiangnan Huang; Daoxin Ma; Wenhao Dong; Peng Li; Ting Lu; Na He; Tian Tian; Na Liu; Yahui DU; Chunyan Ji
Journal:  Oncol Lett       Date:  2013-05-14       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.